Kok TC - Search Results

1

Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.

van der Gaast A, Hulshof C, Kok TC, van Loon E, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Eur J Cancer. 1993;29A(6):870-3. doi: 10.1016/s0959-8049(05)80428-9. Eur J Cancer. 1993. PMID: 8484981

2

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.

Kok TC, van der Gaast A, Splinter TA, Tilanus HW. Kok TC, et al. Eur J Cancer. 1991;27(9):1112-4. doi: 10.1016/0277-5379(91)90305-w. Eur J Cancer. 1991. PMID: 1835618

3

Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma.

Bac DJ, Kok TC, van der Gaast A, Splinter TA. Bac DJ, et al. Among authors: kok tc. J Cancer Res Clin Oncol. 1991;117(3):263-5. doi: 10.1007/BF01625436. J Cancer Res Clin Oncol. 1991. PMID: 2033095

4

Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.

van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Cornillie F, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Br J Cancer. 1994 Mar;69(3):525-8. doi: 10.1038/bjc.1994.95. Br J Cancer. 1994. PMID: 7510117 Free PMC article.

5

Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer.

van der Gaast A, Bontenbal M, Planting AS, Kok TC, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Ann Oncol. 1994 Nov;5(9):858-60. doi: 10.1093/oxfordjournals.annonc.a059020. Ann Oncol. 1994. PMID: 7661927 Free article. Clinical Trial.

6

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer.

van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Hop WC, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Eur J Cancer. 1994;30A(12):1783-6. doi: 10.1016/0959-8049(94)00214-p. Eur J Cancer. 1994. PMID: 7880606

7

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.

van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Eur J Cancer. 1995 Oct;31A(11):1790-3. doi: 10.1016/0959-8049(95)00342-g. Eur J Cancer. 1995. PMID: 8541102 Clinical Trial.

8

Upfront chemotherapy in invasive bladder cancer.

Splinter TA, Kok TC. Splinter TA, et al. Among authors: kok tc. Prog Clin Biol Res. 1992;378:111-6. Prog Clin Biol Res. 1992. PMID: 1301571 Review. No abstract available.

9

What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide.

Splinter TA, van der Gaast A, Kok TC. Splinter TA, et al. Among authors: kok tc. Semin Oncol. 1992 Dec;19(6 Suppl 14):1-7. Semin Oncol. 1992. PMID: 1488650

10

What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.

van der Gaast A, Vlastuin M, Kok TC, Splinter TA. van der Gaast A, et al. Among authors: kok tc. Semin Oncol. 1992 Dec;19(6 Suppl 14):8-12. Semin Oncol. 1992. PMID: 1488657

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters